Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 14/20 | 0.43 |
| ▸ | CCKAR | P32238 | 13/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL6824572 | 1.00 | CCKBR (0.43) | CCKBRCCKARPOLBALDH1A1 | |
| Oxalic Acid SCHEMBL6821968 | 0.99 | CCKBR (0.44) | CCKBRCCKARPOLBALDH1A1 | |
| Oxalic Acid SCHEMBL6821965 | 0.99 | CCKBR (0.44) | CCKBRCCKARPOLBALDH1A1 | |
| SCHEMBL1394355 | 0.96 | CCKBR (0.46) | CCKBRCCKARPOLBALDH1A1 | |
| SCHEMBL6178926 | 0.96 | CCKBR (0.46) | CCKBRCCKARPOLBALDH1A1 | |
| SCHEMBL19949397 | 0.96 | CCKBR (0.46) | CCKBRCCKARPOLBALDH1A1 | |
| SCHEMBL541718 | 0.96 | CCKBR (0.46) | CCKBRCCKARPOLBALDH1A1 | |
| SCHEMBL6193195 | 0.96 | CCKBR (0.46) | CCKBRCCKARPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL6178190 | 0.95 | CCKBR (0.45) | CCKBRCCKARPOLBALDH1A1 | |
| SCHEMBL6180501 | 0.95 | CCKBR (0.44) | CCKBRCCKARPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485179-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20220273803-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2022-09-01 | — | — | US | disclosed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2020-12-10 | — | — | US | disclosed |
| US-10765756-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190076538-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2019-03-14 | — | — | US | disclosed |
| US-10080805-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2018-09-25 | — | — | US | disclosed |
| US-20150050212-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2015-02-19 | — | — | US | disclosed |
| WO-2013126797-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2013-08-29 | — | — | WO | disclosed |
| EP-1234818-B1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | ZERIA PHARM CO LTD (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-6747022-B2 | TREATING DIGESTIVE TRACT DISEASE RESULTING FROM EXCESSIVE SECRETION OF GASTRIC ACID | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1234818-A1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | Zeria Pharmaceutical Co., Ltd. (JP) | 2002-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | CCKBR 1/4885CCKAR 2/4885POLB 4561/4885 |
| US-10765756-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | CCKBR 1/4885CCKAR 2/4885POLB 4561/4885 |
| US-20190076538-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | CCKBR 1/4885CCKAR 2/4885POLB 4561/4885 |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | CCKBR 1/4885CCKAR 2/4885POLB 4561/4885 |
| US-10080805-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | CCKBR 1/4885CCKAR 2/4885POLB 4561/4885 |
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | CCKBR, CCKAR, GABRB1 | CCKBR 1/4885CCKAR 2/4885POLB 3669/4885 |
| US-12485179-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | CCKBR 1/4885CCKAR 2/4885POLB 4561/4885 |
| US-20150050212-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | CCKBR 1/4885CCKAR 2/4885POLB 4561/4885 |
| US-20220273803-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | CCKBR 1/4885CCKAR 2/4885POLB 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.